Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MITO-7: Weekly vs Every 3 Weeks Carboplatin and Paclitaxel in Ovarian Cancer
NCT00660842Phase 3Unknown
- Sponsor
- National Cancer Institute
- Start
- Nov 2008
- Primary completion
- Nov 2024
- Modality
- DNA Intercalators/Alkylators, Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 3 trial of carboplatin, Paclitaxel Micelles for Injection in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by National Cancer Institute. Status: unknown.
02
Drugs
carboplatinPaclitaxel Micelles for Injection
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00660842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00660842.